2450: Post-TED

Centers participating in the CIBMTR must submit a Post-TED (2450) Form for recipients who meet any of the following criteria:

• Recipient receives a transplant at a United States center designated as a TED-only center.
• Recipient receives a transplant at a United States center designated as Comprehensive Report Form center but has been assigned to the TED track by the Form Selection Algorithm.
• Recipient receives an allogeneic transplant at a United States center designated as Comprehensive Report Form center but has not consented to participate in research.
• Recipient receives a transplant at an international center, has consented to participate in research, and has been assigned to the TED track by the Form Selection Algorithm.

The Post-TED fulfills the requirements of the SCTOD for recipients meeting any of the above criteria. For more information regarding the SCTOD, see SCTOD Requirements.

For more information, including information on the TED and Comprehensive Report Form Selection Algorithm, see Section 1 in the Center Reference Guide.

The Post-TED (2450) Form must be completed at the following time points: 100 days, six months, and annually post-infusion. These forms should be completed as closely to these time points as possible. The structure of the TED Forms is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms, except in the case of a subsequent infusion.

*Reporting Data for Each Reporting Period
If the Post-TED (2450) is completed for the Day 100 reporting period, answers to all questions should reflect Day +1 until, and including, the reported Day 100 contact date. For the six-month or annual evaluations, the answers to all questions should reflect since the contact date for the prior reporting period until, and including, the reported contact date for the current reporting period.

*Subsequent Infusions
If the recipient received a subsequent infusion (excluding DLIs, allogeneic boosts using a previous donor for poor graft function / insufficient donor chimerism, and autologous rescues), the answers to all questions should reflect the clinical status of the recipient the day prior to the start of the preparative regimen or, if no preparative regimen was given, the answers to all questions should reflect the clinical status of the recipient the day prior to infusion.

Subsequent Infusions

If a recipient receives a subsequent HCT between Post-TED time points (100 day, six months, annually), the TED form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure or an allogeneic infusion using a prior donor for poor graft function / insufficient donor chimerism, the form sequence will not start over again . Generally, these types of infusions (autologous rescue and allogeneic boosts) are used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease. The Indication for CIBMTR Data Reporting (2814) will come due for both autologous rescues and allogeneic boosts; however, after completing the form, the Donor Cellular Infusion (2199) will come only come due for allogeneic boosts.

Contact the CIBMTR Customer Service Center if the subsequent Pre-TED (2400) does not come due automatically.

Combined Follow-Up

In scenarios where both HCT and cellular therapy forms are being completed, duplicate questions between HCT and cellular therapy forms may be disabled on the Post-TED (2450). A full list of enabled and disabled data fields can be found on the Combined Follow Up section of the Data Management Guide. Illustrations of the combined follow up scenarios can also be found the in the Data Management Guide.

Non-Malignant Diseases

If the HCT being reported was given to treat a non-malignant disease (as reported on the Pre-TED Disease Classification (2402) Form), do not complete the following sections of the Post-TED (2450) Form:

• Disease Assessment at the Time of Best Response to Infusion
• First Relapse or Progression Post-Infusion
• Post-Infusion Intervention for Disease
• Post-Infusion Treatment Given to Prevent Relapse or Progression
• Fecal Microbiota Transplant (FMT)
• Current Disease Status
  

Lost to Follow-Up

Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient’s moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up tool in FormsNet3^SM for each reporting period in which no contact exists.

Links to Sections in Manual:
Q1 – 2: Survival
Q3: Subsequent Transplant
Q4 – 6: Initial ANC Recovery
Q7 – 8: Initial Platelet Recovery
Q9 – 33: Graft-Versus-Host Disease
Q34 – 36: Liver Toxicity Prophylaxis
Q37 – 38: Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Q39: New Malignancy, Lymphoproliferative or Myeloproliferative Disorder
Q40: Chimerism Studies
Q41 – 66: Disease Assessment at the Time of Best Response to Infusion
Q67 – 73: First Relapse or Progression Post-Infusion
Q74 – 76: Recurrence of Non-Malignant Disease
Q77 – 84: Post-Infusion Intervention for Disease
Q85 – 91: Post-Infusion Treatment Given to Prevent Relapse or Progression
Q92 – 95: Fecal Microbiota Transplant
Q96 – 98: Current Disease Status

Manual Updates
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

To reference the historical Manual Change History for this form, review the retired manual section on the Retired Forms Manual webpage.

Date	Manual Section	Add/Remove/Modify	Description
4/24/2026	2450: Post-TED	Modify	Updated when to use the persistent disease option in Q78: Persistent disease: The recipient was in primary induction failure or relapse not in a hematologic CR at the time of infusion and has not achieved a hematologic CR post-infusion. This option is used when there is persistent disease or in cases where there is worsening disease but has not met the progression criteria (i.e., a recipient with MDS who is in NR / SD and has worsening cytopenias. PD cannot be reported as HI has not been previously achieved).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and FMT blue box added to Q92: Combined Follow Up and FMT: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and VOD / SOS blue box added in Q37: Combined Follow-Up and VOD / SOS: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Liver Toxicity Prophylaxis blue box added in Q34: Combined Follow-Up and Liver Toxicity Prophylaxis: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q9: Combined Follow Up GVHD: In scenarios where a CT was given after an HCT and this form is now being completed based on the subsequent CT date, GVHD will always be reported on the Post-TED (2450) Form and is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. In scenarios where both HCT and cell therapy forms are being completed, GHVD questions are disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Secondary Graft Failure blue box added in Q6: Combined Follow Up and Secondary Graft Failure: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, Did secondary graft failure occur? still applies and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q3: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are always reported on the Post-TED (2450) Form and the question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. When both HCT and cell therapy forms are being completed, the subsequent infusion question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Survival Status blue box added to Q2: Combined Follow Up and Survival Status: When both HCT and cell therapy forms are being completed, the survival status on the Post-TED (2450) Form should match the corresponding Post-CTED (4100) Form. If death occurred in the reporting period, Death must be reported as the survival status on both the HCT and cellular therapy forms. Two Recipient Death (2900) Forms will come due; however, only one form needs to be completed. Contact CIBMTR Center Support to remove the duplicate.
1/23/2026	2450: Post-TED	Add	Non-US Centers and Platelet Recovery red warning box added: Non-US Centers and Platelet Recovery: Prior to the Fall 2025 release (October 24, 2025), the platelet recovery questions were optional for non-US centers. However, as of October 24, 2025, this question is now required to be answered for all centers. If completing the Post-TED (2450) Form for a six-month or annual reporting period and the previously completed Post-TED (2450) Form did not require the platelet question to be answered, leave the Was an initial platelet count > 20 × 109/L achieved question blank and override the error as ‘verified correct.’
1/23/2026	2450: Post-TED	Modify	Updated example 3 in Q39: Example 3: A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discreet lesion. Report Yes, there was a new malignancy on the Post-TED (2450) Form, and a single Subsequent Neoplasms (3500) Form will come due to report one of the basal cell malignancies. Create a second Subsequent Neoplasms (3500) form to report the other basal cell malignancy as these are discreet episodes. A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. In the two-year reporting period, the recipient was diagnosed with an additional basal cell skin cancer on the arm. For the one-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 2 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). For the two-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 1 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500).
1/23/2026	2450: Post-TED	Modify	Replaced Recurrent Skin Cancers blue note box with Recurrent Non-Melanoma Skin Cancers blue note box in Q39: Recurrent Skin Cancers: For most malignancies, do not report recurrence, progression or transformation of the recipient’s primary disease (disease for which the infusion was performed) or relapse of a prior malignancy in the “New Malignancy” section. However, for recurrent skin cancers, each discrete lesion should be reported. For example, in the six-month reporting period, a recipient was diagnosed with basal cell skin cancer on the neck four months post-infusion and in the one-year reporting, the recipient was diagnosed with another basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. These discrete episodes should be reported as a ‘new malignancy’ on the Post-TED (2450) Forms. Recurrent Non-Melanoma Skin Cancers: If there is a recurrence of non-melanoma skin cancers in the reporting period, select Yes for Did a new malignancy, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed and a single Subsequent Neoplasms (3500) will come due, allowing the total number of non-melanoma skin cancer lesions diagnosed during the reporting period to be reported. If additional non-melanoma skin cancer lesions are diagnosed in the reporting period, update the reported total number of non-melanoma skin cancer lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). Do not create separate Subsequent Neoplasms (3500) forms for each discrete lesion diagnosed in the reporting period. If a non-melanoma skin cancer is diagnosed again in a future reporting period, repeat the process for that reporting period.
1/23/2026	2450: Post-TED	Modify	Updated Chimerism Studies blue info box above Q40: This section relates to chimerism studies from allogeneic HCTs using cord blood units, or for allogeneic HCT recipients whose primary disease is beta thalassemia or sickle cell disease only a non-malignant. If this was an autologous HCT, an allogeneic HCT using a bone marrow or PBSC product, and / or allogeneic HCT recipient whose primary disease for transplant was not beta thalassemia or sickle cell disease a non-malignant disease, continue to the disease assessment section.
1/23/2026	2450: Post-TED	Add	Clarified how to report the initial therapy start date in Q90 when treatment was started prior to the addition of this question: Indicate if the initial therapy given for reasons other than decrease / loss of chimerism, consolidation therapy, MRD, relapse, persistent, or progressive disease was reported in a previous reporting period. The intent of this question is to capture the start date of the first maintenance therapy administered. If the initial start date was not reported in a prior reporting period, select No and report the initial therapy start date. If maintenance therapy was started, stopped, and restarted, report the date when the therapy first began. If a maintenance therapy was started and then switched to a different maintenance therapy, report the start date of the first maintenance therapy. If initial therapy was started in a previous reporting period and the prior Post-TED (2450) Form did not collect if the initial therapy date was previously reported, select Yes. The therapy start date is not captured for recipients who started their initial therapy prior to the addition of this question. If exact date is not known, refer to General Instructions, General Guidelines for Completing Forms for information about reporting partial or unknown dates.
1/23/2026	2450: Post-TED	Modify	Typo in Q32 – 33 instructions for reporting GVHD steroid treatment correct: These questions are intended to capture if the recipient was still receiving systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents for GVHD on the contact date. Indicate if the recipient was still taking systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents on the contact date. Review the GVHD Reporting Instruction Overview for reporting instructions to these questions.
10/24/2025	2450: Post-TED	Modify	Version 8 of the 2450: Post-TED section of the Forms Instruction Manual released. Version 8 corresponds to revision 9 of the Form 2450.

Copyright © 2004-2026 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.